CRISPR Therapeutics strengthens its technical leadership team with the appointment of industry veteran Dr. Siva Sakhamuri to oversee manufacturing and technical operations.
Appointment of a new Chief Technical Officer with extensive manufacturing experience is a routine leadership change with no immediate financial impact.
CRISPR Therapeutics has named Dr. Siva Sakhamuri as its new Chief Technical Officer, effective immediately. Sakhamuri brings three decades of expertise in biologics, RNA therapeutics, and lipid nanoparticle delivery to the gene-editing firm.
Dr. Siva Sakhamuri has been appointed as the new Chief Technical Officer, bringing extensive experience in manufacturing and RNA therapeutics.